Patients ages @ years with active RA with an inadequate response to @ tumor necrosis factor inhibitor ( TNFi ) and receiving stable background methotrexate were randomized @:@:@:@ to tofacitinib @ mg or @ mg twice daily , or placebo advanced to tofacitinib @ mg or @ mg twice daily at month @ .